Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel agents in the treatment of lung cancer: conference summary statement.
Lynch TJ, Adjei AA, Bunn PA Jr, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Lynch TJ, et al. Among authors: khuri fr. Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4199s-4204s. doi: 10.1158/1078-0432.CCR-040021. Clin Cancer Res. 2004. PMID: 15217958 No abstract available.
Emerging therapies in non-small-cell lung cancer.
Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Free article. Review.
New targets for the treatment of advanced non-small cell lung cancer.
Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS. Massarelli E, et al. Among authors: khuri fr. Cancer Chemother Biol Response Modif. 2002;20:717-61. Cancer Chemother Biol Response Modif. 2002. PMID: 12703232 Review. No abstract available.
Epidermal growth factor receptor biology (IMC-C225).
Kim ES, Khuri FR, Herbst RS. Kim ES, et al. Among authors: khuri fr. Curr Opin Oncol. 2001 Nov;13(6):506-13. doi: 10.1097/00001622-200111000-00014. Curr Opin Oncol. 2001. PMID: 11673692 Review.
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Kris MG, et al. Among authors: khuri fr. JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741. JAMA. 2014. PMID: 24846037 Free PMC article. Clinical Trial.
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. Herbst RS, et al. Among authors: khuri fr. Cancer. 2002 Jul 15;95(2):340-53. doi: 10.1002/cncr.10629. Cancer. 2002. PMID: 12124835 Free article. Clinical Trial.
479 results